Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.44 EUR | -2.40% | -2.40% | +1.24% |
04-22 | BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment | MT |
04-11 | Gerresheimer shares down on outlook, but key contracts confirmed | RE |
Sales 2024 * | 77.05M 83.34M 6.62B | Sales 2025 * | 80.35M 86.91M 6.9B | Capitalization | 35.01M 37.87M 3.01B |
---|---|---|---|---|---|
Net income 2024 * | -1M -1.08M -85.93M | Net income 2025 * | - 0 0 | EV / Sales 2024 * | 0.58 x |
Net Debt 2024 * | 9.8M 10.6M 842M | Net Debt 2025 * | 6.7M 7.25M 576M | EV / Sales 2025 * | 0.52 x |
P/E ratio 2024 * |
-25.7
x | P/E ratio 2025 * |
-122
x | Employees | 1,071 |
Yield 2024 * |
2.46% | Yield 2025 * |
3.48% | Free-Float | 100% |
1 day | -2.40% | ||
1 week | -2.40% | ||
Current month | -2.40% | ||
1 month | -6.87% | ||
3 months | -1.61% | ||
6 months | -10.62% | ||
Current year | +1.24% |
Managers | Title | Age | Since |
---|---|---|---|
Kimmo Herranen
CEO | Chief Executive Officer | 51 | 31/12/04 |
Kalle Lehtonen
DFI | Director of Finance/CFO | 50 | 31/07/23 |
Director/Board Member | 54 | 31/12/93 |
Members of the board | Title | Age | Since |
---|---|---|---|
Risto Koivula
BRD | Director/Board Member | 56 | 15/08/21 |
Chairman | 58 | 30/06/18 | |
Director/Board Member | 56 | 30/04/22 |
Date | Price | Change | Volume |
---|---|---|---|
14/05/24 | 2.44 | -2.40% | 5,726 |
13/05/24 | 2.5 | -0.79% | 810 |
10/05/24 | 2.52 | -6.67% | 5,994 |
08/05/24 | 2.7 | +8.00% | 4,639 |
07/05/24 | 2.5 | 0.00% | 3,970 |
Delayed Quote Nasdaq Helsinki, May 14, 2024 at 02:44 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.24% | 38.72M | |
+9.65% | 7.35B | |
-.--% | 62.2M | |
-17.65% | 60.42M |
- Stock Market
- Equities
- ADMIN Stock